Categories AlphaGraphs, Earnings, LATEST, Other Industries

Wider-than-expected Q2 loss sends Tilray stock lower

Tilray (NASDAQ: TLRY) reported a loss of 32 cents per share in the second quarter, more than double what it reported last year, as rising operating expenses continue to weigh on its bottom-line. This was wider than analysts’ projection of a loss of 25 cents per share.

Revenue came in at $45.9 million, up 371% year-over-year and above analysts’ prediction of $41.1 million, driven by the Manitoba Harvest acquisition, the legalization of the Canadian adult-use market, and growth in Europe.

tilray q2 2019 earnings results

Total kilogram equivalents sold tripled to 5,588 kilograms from 1,514 kilograms in the prior-year period. However, the average net selling price per gram decreased to $4.61 from $6.38 a year ago.

TLRY shares were down 5.9% immediately following the announcement. The stock has tumbled 80% since its IPO last year. However, it has stabilized from April, trading mostly between $40 and $50.

Gross margin increased sequentially to 27% from 23% in the prior quarter.

cannabis stocks performance comparison

Though Tilray has put in a considerable amount of investments into beverage and retail partnerships, there is rising criticism that even these initiatives are overvalued in the markets. It’s hard to be sure though, given we are at the early stages of the cannabis industry.

As Tilray trailed behind its rivals in the medical marijuana segment, it shifted its focus to the abundant opportunities in the CBD-infused food products industry. The acquisition of Manitoba Harvest and more recently, UK-based alcohol gummy maker Smith & Sinclair, were aimed at producing food products based on cannabinoid.

READ: Canopy Growth earnings preview: Q1 crucial in the recent turn of events

In Q2, revenue from Food Products segment grew to $19.9 million, representing almost 43% of total revenues.

cannabis stocks market cap comparison; Canopy Growth, Aurora Cannabis, GW pharmaceuticals, Cronos Group, Tilray, Aphria, Hexo, Village Farms

However, the Federal Drug Administration recently questioned the authenticity and safety aspects of such products, besides initiating the first hearing on it two weeks ago.

Rival Aurora Cannabis (NYSE: ACB) will report earnings results on August 20, while Canopy Growth (NYSE: CGC) will report on August 14.  

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Adobe Inc. (ADBE) Stock: Should you invest in this recession-proof tech firm?

Adobe, Inc. (NASDAQ: ADBE) has been dominating the design software space for quite some time, all along staying resilient to macroeconomic fluctuations and market headwinds. The company’s cloud-based applications, offered

Brilliant Earth IPO: Here are a few points to note about this jewelry company that goes public next week

Jewelry has always played a significant role in people’s lives. As life begins to go back to normal after the pandemic and people start attending social events, they are looking

Kontrol Technologies CEO Paul Ghezzi: Our focus is on reinvesting for growth

Tell us about BioCloud, how it’s different from any alternate existing products, and your distribution model. BioCloud exists as a part of Kontrol Technologies and is an innovation within our

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top